Compared with monotherapy group, combined therapy significantly reduced the weight of tumors in the abdominal cavity and the number of mesenteric dissemination tumor nodules of mice (Fig. 7B,C), suggesting that IL-33 combined with p38 inhibitor has synergistic anti-tumor effect on abdominal dissemination tumors. Here, IL33 is linked to neoplasm.